v3.26.1
Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Numerator:        
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. $ (7,391) $ (6,692) $ (14,424) $ (13,956)
Denominator:        
Weighted average Class A common share outstanding-basic 187,168 36,542 180,038 34,999
Weighted average Class A common share outstanding-diluted 187,168 36,542 180,038 34,999
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted $ (0.04) $ (0.18) $ (0.08) $ (0.4)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-Basic $ (0.04) $ (0.18) $ (0.08) $ (0.4)
Common Class A        
Numerator:        
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. $ (7,391) $ (6,692) $ (14,424) $ (13,956)
Denominator:        
Weighted average Class A common share outstanding-basic [1] 187,168 36,542 180,038 34,999
Weighted average Class A common share outstanding-diluted [1] 187,168 36,542 180,038 34,999
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted $ (0.04) $ (0.18) $ (0.08) $ (0.4)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-Basic $ (0.04) $ (0.18) $ (0.08) $ (0.4)
[1]

*The pre-funded warrants (Note 9) are considered outstanding shares in the basic earnings per share calculation given their nominal exercise price (as of the beginning of the period or the date of the grant, whichever is earlier).